HC Wainwright & Co. Reiterates Buy on Enanta Pharma, Maintains $20 Price Target
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsReiterationPrice Target
HC Wainwright & Co. analyst Brandon Folkes reiterates Enanta Pharma (NASDAQ:ENTA) with a Buy and maintains $20 price target.
HC Wainwright & Co. analyst Brandon Folkes reiterates Enanta Pharma (NASDAQ:ENTA) with a Buy and maintains $20 price target.